Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Exosomes | 2 |
siRNA | 2 |
Chemical drugs | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism NOX inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BAP1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SQSTM1 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date24 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Isuzinaxib ( NOX ) | Diabetic Nephropathies More | Phase 1 |
TG2-179-1 ( BAP1 ) | Colonic Cancer More | Preclinical |
YTK-2205 ( SQSTM1 ) | Castration-Resistant Prostatic Cancer More | Preclinical |
LJ-1888 ( A3R ) | Renal fibrosis More | Preclinical |
KRAS G12C siRNA(Exollence Biotechnology) ( KRAS G12C ) | Non-Small Cell Lung Cancer More | Preclinical |